Search

Your search keyword '"Lim, Darren Wan-Teck"' showing total 146 results

Search Constraints

Start Over You searched for: Author "Lim, Darren Wan-Teck" Remove constraint Author: "Lim, Darren Wan-Teck"
146 results on '"Lim, Darren Wan-Teck"'

Search Results

2. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

6. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

10. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic

13. High-Throughput Microfluidic Extraction of Platelet-free Plasma for MicroRNA and Extracellular Vesicle Analysis

14. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

15. CYP2A6 Genetic Polymorphism and Nicotine Metabolism of Male Smokers in Indonesia.

16. Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer

17. Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.

18. Identifying correlates of post treatment responses for unresectable locally advanced non-small cell lung cancer (LA NSCLC).

19. Association of Claudin-1 overexpression with immune exclusion in nasopharyngeal carcinoma and its potential as a novel therapeutic target.

21. Dearth of smoking-induced mutations in NSRO-driven non-small-cell lung cancer despite smoking exposure

27. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

31. Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model

33. A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).

34. Erytheme au site d'une cicatrice du vaccin bacille de Calmette-Guerin apres l'obtention d'une dose du vaccin a ARN messager contre le SRAS-CoV-2

35. Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma.

37. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

41. Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC)

42. Abstract CT203: A phase II trial of ipilimumab in combination with nivolumab in EBV-associated advanced nasopharyngeal carcinoma (NCT03097939)

44. Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors

45. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy

48. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform

49. Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC)

50. The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).

Catalog

Books, media, physical & digital resources